Neurological
1963–1964, Steele, Richardson, and Olszewski case series, Canada (though earlier undifferentiated cases appeared in 19th-century European neurology records)
Progressive supranuclear palsy was a condition whose distinct identity took centuries to emerge from the broader shadow of Parkinson's disease and other movement disorders. Physicians in earlier eras grouped its characteristic features under various neurological rubrics, leaving patients without a precise diagnosis until the mid-twentieth century. The formal delineation of the condition represented a landmark moment in the history of clinical neurology.
Historical Narrative
For much of medical history, the constellation of features associated with progressive supranuclear palsy was subsumed within descriptions of paralysis agitans or other degenerative conditions of the nervous system. Ancient physicians working within Galenic frameworks attributed disorders of movement and gaze to imbalances of the humors, particularly an excess of black bile thought to corrupt the brain's vital pneuma. Medieval Islamic scholars such as Avicenna catalogued tremors and rigidities in their encyclopedic medical texts, though nothing resembling a discrete clinical portrait of this condition appeared in those early works.
European physicians of the Renaissance and early modern period began more carefully observing patients with movement difficulties, yet the subtleties of vertical gaze palsy and postural instability were rarely distinguished from the generalized category of 'shaking palsy' that James Parkinson would later describe with greater precision in 1817. Parkinson's Essay on the Shaking Palsy provided a framework that dominated neurological thinking for well over a century, and clinicians encountering patients whose presentations diverged from his description often recorded their cases under modified or approximate diagnoses.
The nineteenth century brought histological examination of the nervous system into routine medical practice, and neurologists began using the microscope to look for lesions that might explain unusual motor presentations. Jean-Martin Charcot at the Salpêtrière in Paris was among the most influential figures in systematically categorizing neurological diseases during this era, training a generation of clinicians to distinguish one degenerative condition from another. Yet even within Charcot's extensive nosology, the specific entity later known as progressive supranuclear palsy remained unnamed and unrecognized as a separate disease.
It was not until 1963 and 1964 that Canadian neurologist John Steele, working alongside his colleagues John Richardson and Jerzy Olszewski, published the landmark papers that formally defined the condition as a distinct clinicopathological entity. Their careful study of nine patients, combined with detailed post-mortem examination of brain tissue, revealed a consistent pattern of neurofibrillary tangles and neuronal loss concentrated in the brainstem and basal ganglia. Richardson had first drawn attention to these unusual cases, observing patients whose supranuclear gaze palsy, postural instability, and cognitive changes set them apart from typical Parkinson's disease presentations in ways that demanded a new diagnostic category.
The eponym Steele-Richardson-Olszewski syndrome was widely adopted in recognition of this foundational work, and the condition was subsequently incorporated into the growing literature on what researchers came to call tauopathies — diseases characterized by abnormal accumulations of tau protein in neural tissue. Neuropathologists throughout the latter twentieth century refined the microscopic criteria, while neurologists worked to distinguish the condition from other parkinsonian syndromes that had long been conflated with it. The development of early brain imaging technologies in the 1970s and 1980s offered researchers new tools for observing structural changes in living patients rather than relying solely on post-mortem analysis.
Historically, the story of progressive supranuclear palsy illustrated how conditions affecting relatively small numbers of patients could remain hidden within broader diagnostic categories for generations, awaiting clinicians willing to look closely enough at what made their patients' experiences distinct from established disease portraits.
Key Historical Figures
Historical narrative only — this page describes how Progressive supranuclear palsy was understood historically. It is not medical advice and does not describe current diagnosis or treatment. Sourced from verified medical history references (NIH, Encyclopaedia Britannica, and standard medical history texts). See our medical disclaimer.